3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
2
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Anastomotic Leak
1
Interventions
Fluorouracil
12
Oxaliplatin
11
Leucovorin
10
Irinotecan
7
Capecitabine
7
regorafenib
4
Radiotherapy
4
Bevacizumab
4
aflibercept
2
Reverse Transcriptase Polymerase Chain Reaction
2
Radiation
2
Neoadjuvant Therapy
2
Biopsy
2
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab biosimilar HLX02
1
sulindac sulfone
1
sargramostim
1
pembrolizumab
1
lonafarnib
1
irofulven
1
infigratinib
1
dehydroftorafur
1
balstilimab
1
XELOX
1
Trifluridine
1
Trastuzumab
1
Transplantation
1
Sunitinib
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Rectal Neoplasms
×
Metronidazole
×
Clear all
NCT02682485
2023-04-26
SES-DTA
University of Chicago
Phase 2
Withdrawn